论文部分内容阅读
近年来,生物技术(Bio-technology,简称BT)产业出现了蒸蒸日上之势。由于许多省区对本区域医药产业的优势领域与整体竞争力研究不足,不能正确引导本地医药企业发展与医药群落的形成,造成医药项目和科技园区重复建设,资金与资源严重浪费,有的园区集中污染问题正在凸现。生物制药是否会重蹈化学制药和中成药制造业的老路?是否会出现各自为政的“县县办BT”的情形?这些应引起我们的高度警觉。本文的目的就是通过区位商这个产业结构专业化经济指标来评估我国近几年的生物制药产业,找出哪些地区在生物药业有专业化或地方化优势,并为优化我国生物制药产业结构提出一些建议。
In recent years, the biotechnology (Bio-technology, referred to as BT) industry has booming trend. Many provinces and autonomous regions have not sufficiently studied the advantages and overall competitiveness of the pharmaceutical industry in the region and can not correctly guide the development of local pharmaceutical enterprises and the formation of medical communities. As a result, the construction of pharmaceutical projects and science and technology parks is repeated with serious waste of funds and resources. Some parks are concentrated Pollution is emerging. Will biopharmaceuticals repeat the old path of chemical pharmacy and proprietary Chinese medicine manufacturing industry? Will there be cases of “county-level BTs” operating in isolation? These should arouse our vigilance. The purpose of this paper is to evaluate the biopharmaceutical industry in our country in recent years through the economic quotient of the industrial structure of location providers and to find out which areas have the advantages of specialization or localization in the biopharmaceutical industry and propose the optimization of the biopharmaceutical industrial structure in China some advices.